https://scholars.lib.ntu.edu.tw/handle/123456789/630964
標題: | Association of Major Adverse Cardiac Events and Beta-Blockers in Patients with and without Atherosclerotic Cardiovascular Disease: Long-Term Follow-Up Results of the T-SPARCLE and T-PPARCLE Registry in Taiwan | 作者: | Liu, Patrick Yan-Tyng FANG-JU LIN CHIH-FAN YEH Hsiao, Yu-Chung Hsuan, Chin-Feng WEI-TIEN CHANG HSIEN-LI KAO JIANN-SHING JENG YEN-WEN WU Hsieh, I-Chang Fang, Ching-Chang Wang, Kuo-Yang Chang, Kuan-Cheng Lin, Tsung-Hsien Sheu, Wayne Huey-Herng Li, Yi-Heng Yin, Wei-Hsian Yeh, Hung-I Chen, Jaw-Wen CHAU-CHUNG WU |
關鍵字: | Taiwan cohort; atherosclerotic cardiovascular disease; beta-blocker; event-free survival; major adverse cardiac events | 公開日期: | 10-三月-2023 | 出版社: | MDPI | 卷: | 12 | 期: | 6 | 起(迄)頁: | 2162 | 來源出版物: | Journal of Clinical Medicine | 摘要: | Beta-blockers are widely used, but the benefit is now challenged in patients at risk of atherosclerotic cardiovascular disease (ASCVD) in the present coronary reperfusion era. We aimed to identify the risk factors of a major adverse cardiac event (MACE) and the long-term effect of beta-blockers in two large cohorts in Taiwan. Two prospective observational cohorts, including patients with known atherosclerosis cardiovascular disease (T-SPARCLE) and patients with at least one risk factor of ASCVD but without clinically evident ASCVD (T-PPARCLE), were conducted in Taiwan. The primary endpoint is the time of first occurrence of a MACE (cardiovascular death, nonfatal stroke, nonfatal myocardial infarction, and cardiac arrest with resuscitation). Between December 2009 and November 2014, with a median 2.4 years follow-up, 11,747 eligible patients (6921 and 4826 in T-SPARCLE and T-PPARCLE, respectively) were enrolled. Among them, 273 patients (2.3%) met the primary endpoint. With multivariate Cox PH model analysis, usage of beta-blocker was lower in patients with MACE (42.9% vs. 52.4%, p < 0.01). In patients with ASCVD, beta-blocker usage was associated with lower MACEs (hazard ratio 0.72; p < 0.001), but not in patients without ASCVD. The event-free survival of beta-blocker users remained higher during the follow-up period (p < 0.005) of ASCVD patients. In conclusion, in ASCVD patients, reduced MACE was associated with beta-blocker usage, and the effect was maintained during a six-year follow-up. Prescribing beta-blockers as secondary prevention is reasonable in the Taiwanese population. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/630964 | ISSN: | 2077-0383 | DOI: | 10.3390/jcm12062162 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。